Mark James Litton

CIK 1604834 · PRESIDENT and CEO · last filed 2026-04-13

Mark James Litton is a PRESIDENT and CEO who has filed 46 SEC Form 4 insider transactions across 4 companies since 2014. The most recent filing, for LONA, was dated Apr 13, 2026. Across all open-market trades the lifetime net is −$5.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $315.5K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$315.5K

Companies

Total Filings

Lifetime Open-Market Net

-$5.65M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address

C/O ATHIRA PHARMA, INC.
18706 NORTH CREEK PARKWAY, SUITE 104
BOTHELL, WA 98011

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
LONA	PRESIDENT and CEO	58,582	$5.38	$315.5K	-$27.7K	2	2026-04-13
LeonaBio, Inc. (ATHA) Delisted	President and CEO	44,070	$6.92	$305.0K	-$91.6K	17	2026-01-05
ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted	See Remarks	—	$64.97	—	$0	2	2019-02-08
ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted	Chief Business Officer	132,663	—	—	-$5.53M	21	2018-06-05

Recent Filings

46 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-04-13	LONA	Grant (A)	—	$0	EDGAR
2026-03-05	LONA	Mixed	+17,098	-$27.7K	EDGAR
2026-03-04	LONA	Notice (144)	−5,156	-$27.7K	EDGAR
2026-01-05	LeonaBio, Inc. (ATHA) Delisted	Mixed	+8,248	-$17.8K	EDGAR
2025-12-29	LeonaBio, Inc. (ATHA) Delisted	Grant (A)	—	$0	EDGAR
2025-07-02	LeonaBio, Inc. (ATHA) Delisted	Mixed	+83,211	-$7.4K	EDGAR
2025-07-01	LONA	Notice (144)	−25,123	-$7.4K	EDGAR
2025-03-04	LeonaBio, Inc. (ATHA) Delisted	Grant (A)	—	$0	EDGAR
2025-01-03	LeonaBio, Inc. (ATHA) Delisted	Mixed	+83,226	-$14.1K	EDGAR
2025-01-02	LONA	Notice (144)	−25,107	-$14.1K	EDGAR

Showing 1–10 of 46

Page 1 of 5 Next

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.